Arkadios Wealth Advisors Boosts Holdings in Thermo Fisher Scientific Inc. $TMO

Arkadios Wealth Advisors lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 38.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,467 shares of the medical research company’s stock after purchasing an additional 2,081 shares during the quarter. Arkadios Wealth Advisors’ holdings in Thermo Fisher Scientific were worth $3,622,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently modified their holdings of the stock. Highline Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 126.9% during the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock valued at $29,000 after buying an additional 33 shares during the last quarter. Capital A Wealth Management LLC boosted its holdings in Thermo Fisher Scientific by 825.0% in the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after purchasing an additional 66 shares during the last quarter. DiNuzzo Private Wealth Inc. raised its stake in Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after buying an additional 61 shares during the last quarter. HighMark Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 140.6% during the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after buying an additional 45 shares during the period. Finally, Elevation Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 35.1% in the 3rd quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock worth $37,000 after buying an additional 20 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP Lisa P. Britt sold 10,225 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the completion of the transaction, the vice president owned 14,145 shares in the company, valued at $8,085,564.90. This trade represents a 41.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 17,104 shares of the stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $573.54, for a total value of $9,809,828.16. Following the transaction, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $65,247,057.48. The trade was a 13.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 149,271 shares of company stock valued at $86,507,282 in the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $636.26 on Thursday. The stock has a market cap of $239.05 billion, a PE ratio of 36.76, a P/E/G ratio of 4.07 and a beta of 0.91. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The business’s 50-day simple moving average is $588.78 and its two-hundred day simple moving average is $528.67. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $637.98.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter last year, the business posted $5.28 earnings per share. The firm’s revenue was up 4.9% on a year-over-year basis. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has approved a share repurchase plan on Thursday, November 6th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Stockholders of record on Monday, December 15th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, December 15th. Thermo Fisher Scientific’s payout ratio is 9.94%.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of recent research reports. Morgan Stanley increased their target price on Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Argus raised their price objective on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Citigroup raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and upped their target price for the company from $580.00 to $660.00 in a report on Thursday, December 11th. JPMorgan Chase & Co. lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Finally, Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $625.47.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.